Answers are grounded in this paper and cite their sources.
Introduction Tezepelumab has demonstrated efficacy in patients with severe, uncontrolled asthma in randomized controlled trials (RCTs). Real-world studies assessing patient-reported outcomes are required to complement RCT findings. Methods ASCENT is an ongoing, multi-country, single-arm, prospective, real-world study assessing asthma symptom control in participants (≥12 years old) with severe, uncontrolled asthma initiating tezepelumab as routine standard of care in Europe and Canada. This interim analysis assessed changes from baseline in Asthma Control Questionnaire-6 (ACQ-6) score, St George's Respiratory Questionnaire (SGRQ) total score, and pre-bronchodilator forced expiratory volume in 1 second (FEV 1 ) at weeks 4, 12, and 24, and the annualized asthma exacerbation rate (AAER) in the 52-week baseline and 24-week follow-up periods. Results Overall, 211 participants were included in this analysis. ACQ-6 and SGRQ total scores improved from baseline to week 4 (least-squares mean [95% CI] change: –0.99 [–1.13, –0.84] and –13.2 [–15.6, –10.8], respectively) and further improved to week 24 (–1.28 [–1.44, –1.12] and –19.8 [–22.6, –17.0], respectively). AAER decreased by 65% (95% CI: 55, 73) between baseline (1.75) and follow-up (0.61) periods. Least-squares mean changes from baseline in pre-bronchodilator FEV 1 at weeks 4 and 24 were 0.09 L (0.03, 0.14) and 0.12 L (0.06, 0.18), respectively. These changes were observed across asthma phenotypes and biomarker levels. Conclusion Patients with severe, uncontrolled asthma treated with tezepelumab had clinically meaningful improvements in asthma control, health-related quality of life, lung function, and exacerbations as early as week 4 through to week 24, irrespective of asthma phenotype. Clinical trial number NCT05677139
No takes yet. Share an insight, caveat, or question.
Milger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: